Evidence map›Paper›PMID 29976785›Full record

ArticleEndocrine connections2018

Adherence and long-term growth outcomes: results from the easypod

Ekaterina Koledova, George Stoyanov, Leroy Ovbude, Peter S W Davies

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine connections, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Adherence to Growth Hormone Treatment in Children During the COVID-19 PandemicJournal of clinical research in pediatric endocrinology · 2024
    Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Evaluating the TUITEKFrontiers in endocrinology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Ekaterina KoledovaBiopharma Global Medical Affairs, General Medicine and Endocrinology, Merck KGaA, Darmstadt, Germany.
George StoyanovBiopharma Global Medical Affairs, General Medicine and Endocrinology, Merck KGaA, Darmstadt, Germany.
Leroy OvbudeBusiness & Decision Life Sciences, Brussels, Woluwe-Saint-Lambert, Belgium.
Peter S W DaviesChildren's Nutrition Research Centre, Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
Merck (Germany) · DEUniversity of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe easypod connect observational study (ECOS) assessed treatment adherence among paediatric patients receiving growth hormone (GH) via the easypod electronic injection device.

designECOS was an open-label, observational, longitudinal study conducted in 24 countries between 2010 and 2016, enrolling children treated with GH.

methodsThe primary endpoint was the rate of treatment adherence during 5 years of follow-up. Impact of adherence on growth outcomes was assessed using Spearman's product-moment correlations. RESULTS AND

conclusionsOverall, 1190 patients had easypod data available for ≥3 months; most patients had GH deficiency (75%); 606 of these patients were GH naïve at baseline. Over the first year of monitoring, the median rate of adherence was 93.7% among patients overall and >93.0% in GH-naïve patients, irrespective of the treatment indication. Clinically meaningful improvements in growth rates were observed after 1 year of treatment across all GH indications. Adherence decreased with increasing treatment duration, but the overall median adherence rate remained high after 3 years of follow-up: 87.2% (

conclusionsECOS produced accurate, real-time adherence data in a large population of GH-treated children over 5 years of follow-up. Using the easypod connect system, physicians can potentially identify patients with inadequate adherence and poor response to treatment, enabling them to take appropriate action to help them maximise the benefits of GH treatment.

Indexed as

adherenceeasypode-HealthGH treatment

Identifiers

PMID29976785
PMCPMC6107763
OpenAlexW2830414615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.